Donnelly Richard G 4

4 · AspenBio Pharma, Inc. · Filed Jan 28, 2009

Form 4

Period: 2009-01-27

DirectorPresident & CEO

Transactions

Award
Stock Options
2009-01-27+50,000→ 50,000 total
Exercise: $1.33From: 2009-01-27Exp: 2019-01-27→ Common Stock (50,000 underlying)

Holdings

Common Stock
324,681
Common Stock
(indirect: By IRA)
5,000
Stock Options
Exercise: $0.60From: 2005-02-01Exp: 2015-02-01→ Common Stock (500,000 underlying)
500,000
Stock Options
Exercise: $6.63From: 2008-01-17Exp: 2018-01-17→ Common Stock (50,000 underlying)
50,000
Stock Options
Exercise: $2.96From: 2007-01-24Exp: 2017-01-24→ Common Stock (100,000 underlying)
100,000
Stock Options
Exercise: $1.40From: 2007-01-01Exp: 2016-07-14→ Common Stock (75,000 underlying)
75,000

Footnotes (5)

[F1]Options vest over three years, at the rate of 33.3% at the end of year one, 66.7% at the end of year two, and 100% at the end of year three.
[F2]Options were granted pursuant to Board approval on July 14, 2006 and were exempt from Section 16(b) pursuant to Rule 16b-3(d).
[F3]Options and shares of common stock were granted pursuant to Board approval on January 24, 2007. The aggregate number of stock options granted was 100,000. One-third (33,333) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).
[F4]Options were granted pursuant to Board approval on January 17, 2008. The aggregate number of stock options granted was 50,000. One third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).
[F5]Options were granted pursuant to Board approval on January 27, 2009. One third (16,666) of the options vest each year for three years following the date of grant. This transaction is exempt from Section 16(b) pursuant to Rule 16b-3(d).

Documents

1 file